ERBB2 and breast carcinoma: Interestingly, by performing a drug screen, the authors identified several drugs that were able to relocate lysosomes from the cell periphery to the perinuclear area, which reverted the invasive phenotype and induced lysosome-dependent cell death in HER2 positive breast cancer cells.